AstraZeneca is widely recognized for its expertise in oncology treatments. That reputation showed up in the numbers again this quarter. Strong sales of two key drugs - Enhertu for breast tumors and Imfinzi for lung cancer - helped push profit higher than Wall Street expected.
Investors gave a modest thumbs-up. This helped offset a tough beginning to 2025; prior to the earnings release, the company's shares were down 8% year-to-date.
AstraZeneca reports a 75% success rate on its clinical trials. The company seldom announces setbacks in late-stage trials. Still, not everything goes as planned.
CEO Pascal Soriot acknowledged a recent setback in cardiology, where a drug called Wainua didn't work as expected when combined with another treatment. "Biology is biology it doesn't always deliver what you expect," he said. James Gordon of Barclays remarked that several years earlier, investors were very confident in the company's trial design due to its track record, but recent difficulties in oncology and a setback in cardiology have raised concerns.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
Despite the strong quarter, some analysts remain cautious about the company's long-term growth trajectory. Increased research and development spending to support the pipeline beyond cancer has made the trade-off between revenue growth and profit improvement less favorable, according to Shore Capital's Sean Conroy.
Cancer is still AstraZeneca's main story, but the company has other chapters in the works. One of the most watched is an experimental obesity pill. In a clinical study, participants shed up to 11.8% of their body weight while taking the medication. This positions it as a potential competitor to established treatments from Eli Lilly and Novo Nordisk.
Another drug to watch is tozorakimab, designed for chronic obstructive pulmonary disease. The company projects annual revenue exceeding $5 billion from that experimental therapy.
The company is also aiming high on overall sales. AstraZeneca is aiming for $80 billion in annual sales by 2030, CFO Aradhana Sarin stated. Although analysts predict even greater revenue, she called it a "stretch target." The company also intends to maintain its growth rate post-2030, a factor Sarin described as "probably the most underappreciated part of our story."
Investors will get a clearer picture later this year. Those readouts could shift the stock significantly.
AstraZeneca's core cancer-drug business is performing well, as shown by the earnings beat. Shore Capital's Sean Conroy observed that the trade-off between top-line expansion and profit improvement has become less attractive compared to previous years, due to higher R&D spending required to sustain growth after 2030. Upcoming trial results for Datroway and camizestrant, as well as the experimental obesity pill, will be key catalysts.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
